Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study

Background  Psoriasis is a chronic inflammatory disease associated with an increased cardiovascular risk. Metabolic syndrome is a significant predictor of cardiovascular events.

[1]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[2]  John A Spertus,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Executive Summary , 2005, Critical pathways in cardiology.

[3]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[4]  P. Gisondi,et al.  Plasma homocysteine and folate levels in patients with chronic plaque psoriasis , 2006, The British journal of dermatology.

[5]  Ralph B D'Agostino,et al.  Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. , 2006, The Journal of clinical endocrinology and metabolism.

[6]  Jing Chen,et al.  Prevalence of the metabolic syndrome and overweight among adults in China , 2005, The Lancet.

[7]  J. Shaw,et al.  The metabolic syndrome: prevalence in worldwide populations. , 2004, Endocrinology and metabolism clinics of North America.

[8]  A. Drosos,et al.  Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis , 2004, Annals of the rheumatic diseases.

[9]  B. Balkau,et al.  Comment on the provisional report from the WHO consultation , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[10]  L. Naldi,et al.  Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. , 2005, The Journal of investigative dermatology.

[11]  N. Bornstein,et al.  Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. , 2007, Seminars in arthritis and rheumatism.

[12]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[13]  N. Rose.  Autoimmune diseases. , 1981, Scientific American.

[14]  L Naldi,et al.  Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks , 2005, The British journal of dermatology.

[15]  Daniel B. Shin,et al.  Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.

[16]  E. Sijbrands,et al.  Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. , 2007, Atherosclerosis.

[17]  M. Weichenthal,et al.  Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis , 2006, Archives of Dermatological Research.

[18]  R. Krauss,et al.  Diagnosis and management of the metabolic syndrome , 2005 .

[19]  Cristina Bianchi,et al.  Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. , 2005, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[20]  Tebeb Gebretsadik,et al.  Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. , 2005, Arthritis and rheumatism.

[21]  E. Martínez-Abundis,et al.  Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. , 2003, Journal of the American Academy of Dermatology.

[22]  Richard W Morris,et al.  Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. , 2005, Archives of internal medicine.

[23]  D. Moller,et al.  Metabolic syndrome: a clinical and molecular perspective. , 2005, Annual review of medicine.

[24]  S. Weiss.  Obesity: insight into the origins of asthma , 2005, Nature Immunology.

[25]  G. Krueger,et al.  Psoriasis--recent advances in understanding its pathogenesis and treatment. , 2005, Journal of the American Academy of Dermatology.

[26]  A. Kimball,et al.  The Psychosocial Burden of Psoriasis , 2005, American journal of clinical dermatology.

[27]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[28]  C. Ritchlin,et al.  Metabolic disorders in patients with psoriasis and psoriatic arthritis , 2006, Current rheumatology reports.

[29]  R. D'Agostino,et al.  Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.

[30]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.

[31]  R. Langley,et al.  Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. , 2004, Journal of the American Academy of Dermatology.

[32]  F. Granath,et al.  Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients , 2003, European Journal of Epidemiology.

[33]  A. Hamsten,et al.  Psoriasis is associated with lipid abnormalities at the onset of skin disease. , 2006, Journal of the American Academy of Dermatology.

[34]  Y. Shoenfeld,et al.  Mechanisms of Disease: atherosclerosis in autoimmune diseases , 2006, Nature Clinical Practice Rheumatology.

[35]  Giampiero Girolomoni,et al.  Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. , 2005, European journal of dermatology : EJD.

[36]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[37]  R. Stern,et al.  Epidemiology of psoriatic arthritis in the population of the United States. , 2005, Journal of the American Academy of Dermatology.

[38]  R. Hardy,et al.  The metabolic syndrome: A high-risk state for cancer? , 2006, The American journal of pathology.

[39]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. , 2006, Current opinion in cardiology.

[40]  Daniel B. Shin,et al.  Prevalence of cardiovascular risk factors in patients with psoriasis. , 2022, Central European journal of public health.

[41]  Herbert Tilg,et al.  Adipocytokines: mediators linking adipose tissue, inflammation and immunity , 2006, Nature Reviews Immunology.

[42]  Michael Hinckley,et al.  Impact of obesity and smoking on psoriasis presentation and management. , 2005, Archives of dermatology.

[43]  A. Wahba-Yahav.  Disease concomitance in psoriasis. , 1996, Journal of the American Academy of Dermatology.